Neurobo Pharmaceuticals Inc
General ticker "NRBO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $24.3M
Neurobo Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -19.6%.
Estimated limits based on current volatility of 5.2%: low 2.18$, high 2.43$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.87$, 5.59$]
- 2024-12-30 to 2025-12-30 estimated range: [1.46$, 4.16$]
Financial Metrics affecting the NRBO estimates:
- Negative: Non-GAAP EPS, $ of -3.64 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -36.46 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term NRBO quotes
Long-term NRBO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $15.30MM | $19.63MM | $15.89MM |
| Operating Income | $-15.30MM | $-19.63MM | $-15.89MM |
| Non-Operating Income | $0.01MM | $5.66MM | $3.42MM |
| Interest Expense | $0.00MM | $2.19MM | $0.00MM |
| R&D Expense | $6.55MM | $2.78MM | $9.16MM |
| Income(Loss) | $-15.28MM | $-13.97MM | $-12.47MM |
| Profit(Loss) | $-15.28MM | $-13.97MM | $-12.47MM |
| Stockholders Equity | $14.60MM | $21.75MM | $16.68MM |
| Assets | $16.80MM | $33.53MM | $22.78MM |
| Operating Cash Flow | $-15.13MM | $-11.71MM | $-10.80MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.05MM |
| Investing Cash Flow | $-0.59MM | $0.01MM | $-0.05MM |
| Financing Cash Flow | $22.03MM | $28.68MM | $-0.08MM |
| Earnings Per Share* | $-157.85 | $-19.01 | $-2.46 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.